These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 35121816)

  • 1. Does Omicron hit kids harder? Scientists are trying to find out.
    Kozlov M
    Nature; 2022 Feb; ():. PubMed ID: 35121816
    [No Abstract]   [Full Text] [Related]  

  • 2. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly Reactive SARS-CoV-2-Specific T-Cell Response and Participation of Memory B and T Cells in Patients with Omicron COVID-19 Infection.
    Yadav PD; Sahay RR; Salwe S; Trimbake D; Babar P; Sapkal GN; Deshpande GR; Bhise K; Shete AM; Abraham P; Tripathy AS
    J Immunol Res; 2023; 2023():8846953. PubMed ID: 37881339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent SARS-CoV-2 mutations at Spike D796 evade antibodies from pre-Omicron convalescent and vaccinated subjects.
    Elko EA; Mead HL; Nelson GA; Zaia JA; Ladner JT; Altin JA
    Microbiol Spectr; 2024 Feb; 12(2):e0329123. PubMed ID: 38189279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of risk factors for SARS-CoV-2 infection among healthcare workers during Omicron and Delta dominance periods in Japan.
    Li Y; Yamamoto S; Oshiro Y; Inamura N; Nemoto T; Horii K; Takeuchi JS; Mizoue T; Konishi M; Ozeki M; Sugiyama H; Sugiura W; Ohmagari N
    J Hosp Infect; 2023 Apr; 134():97-107. PubMed ID: 36805085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.
    Suntronwong N; Vichaiwattana P; Klinfueng S; Puenpa J; Kanokudom S; Assawakosri S; Chansaenroj J; Srimuan D; Thatsanatorn T; Songtaisarana S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    PLoS One; 2023; 18(4):e0279147. PubMed ID: 37104299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity.
    Joung SY; Ebinger JE; Sun N; Liu Y; Wu M; Tang AB; Prostko JC; Frias EC; Stewart JL; Sobhani K; Cheng S
    JAMA Netw Open; 2022 Aug; 5(8):e2227241. PubMed ID: 35976645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing contributions of airborne route in SARS-CoV-2 omicron variant transmission compared with the ancestral strain.
    Ji S; Xiao S; Wang H; Lei H
    Build Environ; 2022 Aug; 221():109328. PubMed ID: 35784591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational Analysis of Circulating Omicron SARS-CoV-2 Lineages in the Al-Baha Region of Saudi Arabia.
    Almalki SSR; Izhari MA; Alyahyawi HE; Alatawi SK; Klufah F; Ahmed WAM; Alharbi R
    J Multidiscip Healthc; 2023; 16():2117-2136. PubMed ID: 37529147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severity of SARS-CoV-2 infection in pregnant women and their neonates during the Omicron period compared to the pre-Omicron period: A retrospective cohort study.
    Yamaguchi T; Makino Y; Mabuchi Y; Okuda K; Hayashi H; Kato N; Fujii T; Hirate H
    J Obstet Gynaecol Res; 2023 May; 49(5):1348-1354. PubMed ID: 36781158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative proteomics and metabolomics study reveal enhanced immune responses by COVID-19 vaccine booster shot against Omicron SARS-CoV-2 infection.
    Wang B; Yang W; Tong Y; Sun M; Quan S; Zhu J; Zhang Q; Qin Z; Ni Y; Zhao Y; Wang K; Zhang C; Zhang Y; Wang Z; Song Z; Liu H; Fang H; Kong Z; Ding C; Guo W
    J Med Virol; 2023 Nov; 95(11):e29219. PubMed ID: 37966997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical characteristics and outcomes of critically ill adults with SARS-CoV-2 infection during Delta and Omicron variant predominance periods: a single-hospital retrospective cohort study.
    Sankar K; Modi N; Polyak A; Directo MP; Johnson LR; Kho N; Isonaka SK; Pedraza I; Chen P; Modes ME
    BMJ Open Respir Res; 2023 Feb; 10(1):. PubMed ID: 36805880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection.
    Stich M; Benning L; Speer C; Garbade SF; Bartenschlager M; Kim H; Jeltsch K; Tabatabai J; Niesert M; Janda A; Renk H; Elling R; Hoffmann GF; Kräusslich HG; Müller B; Bartenschlager R; Tönshoff B
    J Med Virol; 2023 Mar; 95(3):e28582. PubMed ID: 36794653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland.
    Portmann L; de Kraker MEA; Fröhlich G; Thiabaud A; Roelens M; Schreiber PW; Troillet N; Iten A; Widmer A; Harbarth S; Sommerstein R;
    JAMA Netw Open; 2023 Feb; 6(2):e2255599. PubMed ID: 36790812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
    Krutikov M; Stirrup O; Nacer-Laidi H; Azmi B; Fuller C; Tut G; Palmer T; Shrotri M; Irwin-Singer A; Baynton V; Hayward A; Moss P; Copas A; Shallcross L;
    Lancet Healthy Longev; 2022 May; 3(5):e347-e355. PubMed ID: 35531432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.